marked.bio

KRAS cancer vaccine ยท vaccine

ELI-002

2 active trials across 2 of our biomarkers, targeting mutant KRAS. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 2 3 Phase 1/2
KRAS G12D 2 3 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of ELI-002.

  1. Elicio Therapeutics 1

Trials

2 of 3 trials shown

  1. A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

    Active, not recruiting Phase 1/2 Elicio Therapeutics Started 2023Primary completion 2026-04 NCT05726864

    ELI-002

    KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor

    KRAS G12CKRAS G12DPancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R

  2. A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

    Recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2028-06 NCT07671339

    ELI-002tislelizumabmFOLFIRINOX

    Presence of one of seven KRAS mutations: G12D, G12V, G12R, G12C, G12A, G12S, or G13D.

    KRAS G12CKRAS G12DPancreatic Cancer